4 Results for "

erythroid precursor

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "erythroid precursor" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-P99720
CAS No.: 1373715-00-4
Synonyms: ACE-536; luspatercept–aamt

Target:  

TGF-beta/Smad

Research Areas:  

Cardiovascular Disease

Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P81133
Synonyms: Clgi; Collagenase inhibitor; EPA; EPO; erythroid Potentiating Activity; Fibroblast collagenase inhibitor; FLJ90373; HC; Human Collagenase Inhibitor; Metalloproteinase inhibitor 1; Metalloproteinase inhibitor 1 precursor; OTTHUMP00000023214; TIMP 1; TIMP; TIMP metallopeptidase inhibitor 1; TIMP1 protein; Tissue Inhibitor of Metalloproteinase 1; Tissue inhibitor of metalloproteinases; Ttissue inhibitor of metalloproteinase 1 erythroid potentiating activity collagenase inhibitor.

Host:  

Rabbit

Application:  

WB, IHC-P, ICC/IF

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P99720A
CAS No.: 1373715-00-4
Synonyms: RAP-536

Target:  

TGF-beta/Smad

Research Areas:  

Metabolic Disease

Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .
loading...
    loading...
Cat. No.: HY-P991881
KY1070 is a fully human anti-BMP6 antibody with a Kd of 0.00014 μM against the human BMP6. It exhibits high specificity for BMP6, showing no cross-reactivity with other members of the BMP family, and effectively inhibits BMP6-induced BMP receptor heterodimerization and hepcidin expression. KY1070 modulates Ferroportin expression on erythroid progenitor cells and accelerates erythropoiesis. In rodent anemia models, KY1070 reduces the required dose of erythropoietin (EPO) when used in combination with EPO and enhances the responsiveness of mice with chronic kidney disease (CKD)-associated anemia to EPO treatment. KY1070 is applicable for research on anemia of chronic disease [1] [2].
loading...
    loading...